Although there is a good range of cerebrospinal fluid (CSF) diagnostic biomarkers, there is a need for better prognostic markers to predict Alzheimer’s disease (AD) progression as highlighted by Alberto Lleó, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. AD is often associated with co-pathologies which can impact the prognosis of the disease. Dr Lleó suggests these co-pathologies may be tracked via identification of additional biomarkers, like TDP-43 and α-synuclein. This interview took place at the Harvard European Alumni Training Network (HEAT-Net) 2021 congress.